Pay in 4 interest-free payments of $27.00 Learn more
Ships within 48 hours · Estimated delivery Jul 26 - Jul 31
Favipiravir inhibits in a dose-dependent manner MNV-induced CPE (EC50: 250±11 μM) and MNV RNA synthesis in cell culture (EC50:124±42 μM)
H2O4S/c1-5-21(36
ISRIB (trans-isomer)
S-(+)-Rolipram reduces OA-induced bronchoconstriction with ID50 values of approximately 0
SRT 1720 Hydrochloride - CAS# 1001645-58-4 apram Favipiravir inhibits in a dose-dependentSRT 1720, also known as CAY10559 and is a drug developed by Sirtris Pharmaceuticals intended as a small molecule activator of the sirtuin subtype SIRT1. It has similar activity in the body to the known SIRT1 activator resveratrol, but is 1000x more potent. In animal studies it was found to improve insulin sensitivity and lower plasma glucose levels in fat, muscle and liver tissue, and increased mitochondrial and metabolic function. A study of SRT1720